Intravenous Haloperidol Dosing for Adults
For acute agitation in adults, start with haloperidol 2-5 mg IV/IM, with subsequent doses every 4-8 hours as needed (or as frequently as every hour in severe cases), with a maximum of 20 mg/day. 1
Initial Dosing
The FDA-approved dosing for parenteral haloperidol provides the following framework 1:
- Standard initial dose: 2-5 mg IV/IM for prompt control of acute agitation
- Repeat dosing interval: Every 4-8 hours as needed, though doses can be given as frequently as every hour in severe cases
- Maximum daily dose: 20 mg/day
Dose Adjustments for Special Populations
Elderly and Debilitated Patients
Reduce the initial dose substantially in elderly patients - the evidence strongly supports lower starting doses in this population:
- Recommended starting dose: 0.5-1 mg IV/IM 2
- Maximum daily dose: 5 mg/day (compared to 10 mg/day in younger adults) 2
- Dose escalation: Increase in 0.5-1 mg increments as needed 2
The 2020 NICE guidelines provide the most recent guidance, emphasizing that elderly patients require half the maximum dose of younger patients 2. Recent research from 2023 supports that low-dose haloperidol (≤0.5 mg) demonstrates similar efficacy to higher doses in older hospitalized patients, with better safety outcomes 3. A 2013 retrospective study found that higher than recommended doses in elderly patients resulted in increased sedation without improving agitation duration or hospital length of stay 4.
Hepatic Impairment
While the FDA label notes that debilitated patients require lower doses 1, specific hepatic dosing adjustments are not explicitly provided in the evidence. Use the lower end of the dosing range (0.5-1 mg initially) and titrate cautiously in patients with hepatic impairment, as haloperidol undergoes hepatic metabolism.
Continuous Infusion Dosing
For severe, refractory agitation in critically ill patients, continuous IV infusion at 2.5-10 mg over 24 hours can be considered 2. Research from 1994 documented safe use of continuous infusions ranging from 3-25 mg/hour in mechanically ventilated patients with severe agitation 5.
Dosing for Severe Agitation
For patients who are severely distressed or causing immediate danger, consider a higher starting dose of 1.5-3 mg 2. Historical case reports from 1985 documented safe use of >100 mg/day IV haloperidol in severely agitated cardiac patients, though such high doses are rarely necessary with modern protocols 6.
Route Equivalence
The same dose of haloperidol may be administered subcutaneously or IV as would be given orally 2. This 1:1 conversion simplifies transitions between routes.
Critical Safety Considerations
QTc Prolongation Risk
All antipsychotics, including haloperidol, prolong the QTc interval at therapeutic doses, though typically not exceeding 500 ms 7. Obtain baseline ECG in patients with cardiac risk factors and monitor for QTc prolongation, particularly with higher doses or continuous infusions.
Extrapyramidal Symptoms
The 2006 emergency medicine guidelines note that haloperidol at 5 mg doses showed comparable efficacy to lorazepam for agitation 7. However, avoid routine use of anticholinergics like benztropine for prophylaxis 8 - only treat documented extrapyramidal symptoms if they occur. A 2022 study found that patients receiving haloperidol plus lorazepam (without diphenhydramine) had better safety outcomes than the "B52" combination 9.
Combination Therapy
Consider adding a benzodiazepine (lorazepam 0.5-1 mg or midazolam 2.5-5 mg) if agitation persists despite adequate haloperidol dosing 2. The 2006 guidelines note that benzodiazepines are at least as effective as haloperidol alone for agitation control 7.
Transition to Oral Therapy
Switch to oral haloperidol within 12-24 hours of the last parenteral dose 1. Use the total 24-hour parenteral dose as an initial approximation for the oral daily dose, monitoring closely for the first several days and adjusting based on clinical response.
Common Pitfalls
- Avoid excessive dosing in elderly patients - doses >5 mg/day increase adverse effects without improving efficacy 3, 4
- Do not use haloperidol for delirium prevention - a 2018 ICU guideline recommends against prophylactic use 10
- Monitor for respiratory depression when combining with benzodiazepines or opioids - synergistic sedation can occur
- Recognize that anticholinergic toxicity or sympathomimetic intoxication may worsen with haloperidol due to its anticholinergic properties 7